{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:26:45Z","timestamp":1790965605929,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05103-6","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T08:10:15Z","timestamp":1774253415000},"page":"4353-4358","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Observation on the short-term efficacy of telitacicept in the treatment of primary IgA nephropathy"],"prefix":"10.1007","volume":"58","author":[{"given":"Xiaoling","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"5","key":"5103_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","volume":"38","author":"FP Schena","year":"2018","unstructured":"Schena FP, Nistor I (2018) Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol 38(5):435\u2013442. https:\/\/doi.org\/10.1016\/j.semnephrol.2018.05.013. (PMID: 30177015)","journal-title":"Semin Nephrol"},{"issue":"3","key":"5103_CR2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","volume":"8","author":"J Lv","year":"2022","unstructured":"Lv J, Liu L, Hao C, Li G, Fu P, Xing G, Zheng H, Chen N, Wang C, Luo P, Xie D, Zuo L, Li R, Mao Y, Dong S, Zhang P, Zheng H, Wang Y, Qin W, Wang W, Li L, Jiao W, Fang J, Zhang H (2022) Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney Int Rep 8(3):499\u2013506. https:\/\/doi.org\/10.1016\/j.ekir.2022.12.014. (PMID:36938094;PMCID:PMC10014376)","journal-title":"Kidney Int Rep"},{"issue":"1","key":"5103_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000540326","volume":"149","author":"L Liu","year":"2025","unstructured":"Liu L, Liu Y, Li J, Tang C, Wang H, Chen C, Long H, Chen X, Xing G, Cheng J, Liang J, Peng X, Wang L, Shao S, Lin Y, Chen T, Tang Y, Shen S, Sun L, Wu H, Yu Y, Du X, Liu H, He L, Liu H, Ye M, Chen W, Wen Q, Zhang H, Cao H, Yuan J, Chen H, Wang M, Lv J, Zhang H (2025) Efficacy and safety of telitacicept in IgA nephropathy: a retrospective. Multicenter Study Nephron 149(1):1\u201310. https:\/\/doi.org\/10.1159\/000540326. (Epub 2024 Sep 9 PMID: 39250892)","journal-title":"Multicenter Study Nephron"},{"issue":"1","key":"5103_CR4","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2025.2449580","volume":"47","author":"L Dong","year":"2025","unstructured":"Dong L, Yang D, Qin A, Wang S, Tang Y, Tan J, Qin W (2025) Efficacy and safety of Telitacicept in IgA nephropathy: a real-world study. Ren Fail 47(1):2449580. https:\/\/doi.org\/10.1080\/0886022X.2025.2449580","journal-title":"Ren Fail"},{"issue":"10","key":"5103_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae285","volume":"17","author":"M Wang","year":"2024","unstructured":"Wang M, Ma J, Yao L, Fan Y (2024) Efficacy and safety of Telitacicept, a BLyS\/APRIL dual inhibitor, in the treatment of IgA nephropathy: a retrospective case-control study. Clin Kidney J 17(10):sfae285. https:\/\/doi.org\/10.1093\/ckj\/sfae285","journal-title":"Clin Kidney J"},{"key":"5103_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.clim.2016.07.011","volume":"172","author":"J Mestecky","year":"2016","unstructured":"Mestecky J, Novak J, Moldoveanu Z, Raska M (2016) IgA nephropathy enigma. Clin Immunol 172:72\u201377. https:\/\/doi.org\/10.1016\/j.clim.2016.07.011","journal-title":"Clin Immunol"},{"issue":"14","key":"5103_CR7","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S (2021) Telitacicept: first approval. Drugs 81(14):1671\u20131675. https:\/\/doi.org\/10.1007\/s40265-021-01591-1. (PMID: 34463932)","journal-title":"Drugs"},{"issue":"4","key":"5103_CR8","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.ekir.2024.01.003","volume":"9","author":"J Zan","year":"2024","unstructured":"Zan J, Liu L, Li G, Zheng H, Chen N, Wang C, Xie D, Zuo L, Li R, Zhang P, Wang Y, Wang W, Li L, Fang J, Lv J, Zhang H (2024) Effect of telitacicept on circulating Gd-IgA1 and IgA-containing immune complexes in IgA nephropathy. Kidney Int Rep 9(4):1067\u20131071. https:\/\/doi.org\/10.1016\/j.ekir.2024.01.003. (PMID:38765591;PMCID:PMC11101733)","journal-title":"Kidney Int Rep"},{"issue":"4S","key":"5103_CR9","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100(4S):S1\u2013S276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021","journal-title":"Kidney Int"},{"issue":"4","key":"5103_CR10","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1093\/ndt\/gfr527","volume":"27","author":"W Le","year":"2012","unstructured":"Le W, Liang S, Hu Y, Deng K, Bao H, Zeng C, Liu Z (2012) Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transpl 27(4):1479\u20131485. https:\/\/doi.org\/10.1093\/ndt\/gfr527. (Epub 2011 Sep 29 PMID: 21965586)","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"5103_CR11","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1053\/j.ajkd.2007.03.013","volume":"49","author":"C Manno","year":"2007","unstructured":"Manno C, Strippoli GF, D\u2019Altri C, Torres D, Rossini M, Schena FP (2007) A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study. Am J Kidney Dis 49(6):763\u2013775. https:\/\/doi.org\/10.1053\/j.ajkd.2007.03.013. (PMID: 17533019)","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"5103_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1053\/j.ajkd.2019.11.008","volume":"76","author":"GZ Yu","year":"2020","unstructured":"Yu GZ, Guo L, Dong JF, Shi SF, Liu LJ, Wang JW, Sui GL, Zhou XJ, Xing Y, Li HX, Lv JC, Zhang H (2020) Persistent hematuria and kidney disease progression in IgA nephropathy: a cohort study. Am J Kidney Dis 76(1):90\u201399. https:\/\/doi.org\/10.1053\/j.ajkd.2019.11.008. (Epub 2020 Mar 18 PMID: 32197881)","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"5103_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/bcp.12908","volume":"82","author":"X Chen","year":"2016","unstructured":"Chen X, Zhao Q, Hou Y, Jiang J, Zhong W, Wang W, Yao X, Li L, Fang J, Zhang F, Hu P (2016) Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS\/APRIL fusion protein, in patients with rheumatoid arthritis. Br J Clin Pharmacol 82(1):41\u201352. https:\/\/doi.org\/10.1111\/bcp.12908","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"5103_CR14","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1177\/09612033221097812","volume":"31","author":"L Sun","year":"2022","unstructured":"Sun L, Shen Q, Gong Y, Li Y, Lv Q, Liu H, Zhao F, Yu H, Qiu L, Li X, He X, Chen Y, Xu Z, Xu H (2022) Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: A self-controlled before-after trial. Lupus 31(8):998\u20131006. https:\/\/doi.org\/10.1177\/09612033221097812. (Epub 2022 May 2 PMID: 35499216)","journal-title":"Lupus"},{"issue":"4","key":"5103_CR15","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","volume":"83","author":"D Wu","year":"2024","unstructured":"Wu D, Li J, Xu D, Merrill JT, van Vollenhoven RF, Liu Y, Hu J, Li Y, Li F, Huang C, Wang G, Li X, Zhao J, Zhao D, Huang C, Liu H, Wei W, Shi G, Lu F, Zuo X, Bi L, Li Z, Wang X, Zhang M, Tie N, Li J, Mo H, Fang J, Bao C, Zhang F (2024) Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 83(4):475\u2013487. https:\/\/doi.org\/10.1136\/ard-2023-224854. (PMID: 38129117; PMCID: PMC10958275)","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"5103_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/life11040315","volume":"11","author":"CM Barbagallo","year":"2021","unstructured":"Barbagallo CM, Cefal\u00f9 AB, Giammanco A, Noto D, Caldarella R, Ciaccio M, Averna MR, Nardi E (2021) Lipoprotein abnormalities in chronic kidney disease and renal transplantation. Life 11(4):315. https:\/\/doi.org\/10.3390\/life11040315. (PMID: 33916487; PMCID: PMC8067409.)","journal-title":"Life"},{"issue":"3","key":"5103_CR17","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1053\/j.ajkd.2014.10.005","volume":"65","author":"MJ Sarnak","year":"2015","unstructured":"Sarnak MJ, Bloom R, Muntner P, Rahman M, Saland JM, Wilson PW, Fried L (2015) KDOQI US commentary on the 2013 KDIGO clinical practice guideline for lipid management in CKD. Am J Kidney Dis 65(3):354\u2013366. https:\/\/doi.org\/10.1053\/j.ajkd.2014.10.005. (Epub 2014 Nov 18. PMID: 25465166.)","journal-title":"Am J Kidney Dis"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05103-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05103-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05103-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:53:04Z","timestamp":1789631584000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05103-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":17,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["5103"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05103-6","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"19 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}